​

Genmab (GMAB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GMAB Stock Forecast

Genmab (GMAB) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $45.00, with a high of $45.00 and a low of $45.00. This represents a 124.55% increase from the last price of $20.04.

$20 $25 $30 $35 $40 $45 High: $45 Avg: $45 Low: $45 Last Closed Price: $20.04

GMAB Stock Rating

Genmab stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (68.75%), 4 Hold (25.00%), 1 Sell (6.25%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 1 4 11 Strong Sell Sell Hold Buy Strong Buy

GMAB Price Target Upside V Benchmarks

TypeNameUpside
StockGenmab124.55%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$45.00$45.33
Last Closing Price$20.04$20.04$20.04
Upside/Downside-124.55%126.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25134--8
Mar, 25235--10
Feb, 25225--9
Jan, 25225--9
Dec, 24225--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 11, 2025Asthika GoonewardeneTruist Financial$45.00$20.26122.11%124.55%
Sep 04, 2024Vikram PurohitMorgan Stanley$31.00$27.4113.10%54.69%
Aug 09, 2024Etzer DaroutBMO Capital$46.00$27.0769.93%129.54%
Jun 27, 2024Kaveri PohlmanBTIG$47.00$25.6783.09%134.53%
Jun 27, 2024Raghuram SelvarajuH.C. Wainwright$50.00$25.7194.48%149.50%
Jun 04, 2024Asthika GoonewardeneTruist Financial$53.00$28.8383.84%164.47%
Feb 23, 2024Etzer DaroutBMO Capital$48.00$29.1664.61%139.52%
Feb 06, 2023Leerink Partners$36.00$38.26-5.91%79.64%
Nov 28, 2022Matthew HarrisonMorgan Stanley$34.00$44.83-24.16%69.66%
May 02, 2022Cowen & Co.$38.00$34.918.85%89.62%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2025William BlairMarket PerformOutperformupgrade
Oct 16, 2024H.C. WainwrightBuyBuyhold
Oct 11, 2024Cowen & Co.HoldHoldhold
Sep 20, 2024Johnson RiceBuyBuyhold
Sep 13, 2024H.C. WainwrightBuyBuyhold
Sep 09, 2024Morgan StanleyBuyBuyhold
Aug 20, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024Cowen & Co.HoldHoldhold
Aug 09, 2024BMO CapitalOutperformOutperformhold
Aug 01, 2024BTIGUnderperformUnderperformhold

Financial Forecast

EPS Forecast

$0 $14 $28 $42 $56 $70 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.30$4.60$8.45$66.64-----
Avg Forecast$7.14$4.37$9.88$7.48$8.66$9.62$12.41$17.92$22.36
High Forecast$7.53$4.60$10.45$8.36$9.91$14.02$14.13$20.13$23.89
Low Forecast$6.65$4.06$8.83$6.85$7.76$7.48$8.31$15.91$19.63
Surprise %2.24%5.26%-14.47%790.91%-----

Revenue Forecast

$5B $13B $21B $29B $37B $45B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.11B$8.48B$14.60B$16.47B-----
Avg Forecast$9.75B$8.39B$14.05B$16.16B$21.64B$25.39B$29.23B$33.61B$39.61B
High Forecast$10.16B$8.74B$14.68B$16.44B$22.57B$26.31B$29.40B$33.81B$41.70B
Low Forecast$9.23B$7.94B$12.91B$15.89B$20.78B$24.04B$29.06B$33.41B$35.89B
Surprise %3.65%1.10%3.89%1.92%-----

Net Income Forecast

$0 $8B $16B $24B $32B $40B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.76B$2.96B$5.45B$4.35B-----
Avg Forecast$29.77B$15.19B$14.90B$4.35B$582.45M$708.62M$739.70M$1.19B$1.47B
High Forecast$35.72B$18.22B$17.88B$5.22B$653.26M$924.29M$931.50M$1.33B$1.57B
Low Forecast$23.81B$12.15B$11.92B$3.48B$511.65M$492.95M$547.90M$1.05B$1.29B
Surprise %-84.02%-80.53%-63.41%------

GMAB Forecast FAQ

Is Genmab stock a buy?

Genmab stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Genmab is a favorable investment for most analysts.

What is Genmab's price target?

Genmab's price target, set by 16 Wall Street analysts, averages $45 over the next 12 months. The price target range spans from $45 at the low end to $45 at the high end, suggesting a potential 124.55% change from the previous closing price of $20.04.

How does Genmab stock forecast compare to its benchmarks?

Genmab's stock forecast shows a 124.55% upside, outperforming the average forecast for the healthcare stocks sector (35.94%) and outperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Genmab over the past three months?

  • April 2025: 12.50% Strong Buy, 37.50% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 20.00% Strong Buy, 30.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.22% Strong Buy, 22.22% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.

What is Genmab’s EPS forecast?

Genmab's average annual EPS forecast for its fiscal year ending in December 2024 is $8.66, marking a -87.00% decrease from the reported $66.64 in 2023. Estimates for the following years are $9.62 in 2025, $12.41 in 2026, $17.92 in 2027, and $22.36 in 2028.

What is Genmab’s revenue forecast?

Genmab's average annual revenue forecast for its fiscal year ending in December 2024 is $21.64B, reflecting a 31.37% increase from the reported $16.47B in 2023. The forecast for 2025 is $25.39B, followed by $29.23B for 2026, $33.61B for 2027, and $39.61B for 2028.

What is Genmab’s net income forecast?

Genmab's net income forecast for the fiscal year ending in December 2024 stands at $582.45M, representing a -86.62% decrease from the reported $4.35B in 2023. Projections indicate $708.62M in 2025, $739.7M in 2026, $1.19B in 2027, and $1.47B in 2028.